Results 81 to 90 of about 24,867 (223)

The PRAGMATIC pathway ‐ PRostate cancer diAGnosis and MAnagement Triage In Clinical care

BJU International, EarlyView.
Objectives To investigate whether nurse navigator‐led triaging of high‐risk patients may reduce prostate cancer (PCa) diagnosis and treatment times using an in‐house bespoke PRostate cancer diAGnosis and MAnagement Triage In the Clinial care pathway (PRAGMATIC) triaging system, as locally advanced/metastatic disease should be diagnosed and treated ...
Abhishek Sharma, Teresa Campbell, Sagar Kanabar, Hannah Soanes, Ganesh Sathanapally, Anthony Bates, Rincy John, Charlotte Adams, Aisling Brassill, Bryony Lennon, Sanjay Sinha, Louise Flaxman, Vanessa von Hasseln, Philip Camilleri, Ami Sabharwal, Philip Charlton, Gerard Andrade, Mark Tuthill, Andrew Protheroe, Alastair D. Lamb, Tom Leslie, Aaron Leiblich, Francisco Lopez, Clare Verrill, Fergus Gleeson, Ruth MacPherson, Freddie C. Hamdy, Richard Bell, Richard J. Bryant   +28 more
wiley   +1 more source

Court Child Experts' Experiences in Assessing Parenting Cases Involving Parental Mental Illness

Child &Family Social Work, EarlyView.
ABSTRACT This study explores the experiences of Court Child Experts (CCEs), professionals employed by the Australian family courts, in parenting matters involving parental mental illness. Using interpretative phenomenological analysis, interviews were conducted with five senior CCEs who reflected on their assessment practices, the challenges associated
Taegan A. Holford, Andrea E. Reupert
wiley   +1 more source

Impact of Oral Hygiene Instructions in the Resolution of Peri‐Implant Mucositis. A Randomized Controlled Trial

Clinical Oral Implants Research, EarlyView.
ABSTRACT Aim To determine whether oral hygiene instructions (OHI) alone can be effective in the treatment of peri‐implant mucositis (PM). Material and Methods A randomized clinical trial with 56 PM patients was conducted. Participants were assigned to OHI (n = 28) or OHI + Mechanical Instrumentation (MI) (n = 28). Clinical [modified bleeding index (mBI)
Beatriz de Tapia, Álvaro Babiano, Maria Vittoria Oreglia, Cristina Valles, Jose Nart   +4 more
wiley   +1 more source

Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation

ClinicoEconomics and Outcomes Research, 2020
Lucrezia Ferrario,1 Fabrizio Schettini,1 Elisabetta Garagiola,1 Adriana Cecchi,2 Lucia Lugoboni,3 Paolo Serra,4 Emanuele Porazzi,1 Emanuela Foglia1 1Carlo Cattaneo – LIUC University and LIUC Business School, Castellanza, Italy; 2ARCS &ndash ...
Ferrario L, Schettini F, Garagiola E, Cecchi A, Lugoboni L, Serra P, Porazzi E, Foglia E   +7 more
doaj  

Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Objective To comprehensively assess the cost‐utility of icodec, the first once‐weekly basal insulin, at 700 and 1050 U formulations compared with once‐daily basal insulin analogues in Chinese adults with type 2 diabetes within reimbursement context.
Xichen Tong, Chang Xing, Lei Zhang, Luying Zhang   +3 more
wiley   +1 more source

A Type 2 Diabetes Policy Model That Predicts Remaining Life Expectancy, Quality‐Adjusted Life Expectancy and Healthcare Costs for Use in Economic Evaluation, Incorporating Equity Concerns

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To illustrate a T2DM policy model incorporating socio‐economic status. Materials and Methods Using the Scottish Diabetes Research Network (SDRN) national diabetes cohort, we identified individuals newly diagnosed with T2DM between 1 January 2004 and 31 December 2020 and followed from diagnosis until death or end of follow‐up.
Lili Wei, Houra Haghpanahan, Sarah H. Wild, Claudia Geue, Elaine Butterly, Peter McMeekin, Stuart McGurnaghan, Luke A. K. Blackbourn, Robert Lindsay, David McAllister, Jim Lewsey   +10 more
wiley   +1 more source

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Objectives CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R
Catherine Thieblemont, Florian Colrat, Rahma Sellami, Marine Sivignon, Adrien Petel, Sébastien Branchoux, Gérard de Pouvourville   +6 more
wiley   +1 more source

Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) is a central biomarker in multiple myeloma (MM), offering unprecedented sensitivity for evaluating treatment efficacy and serving as a potential surrogate endpoint. We conducted a comprehensive analysis of clinical trials registered on ClinicalTrials.gov between 2014 and 2025.
Mimi Choon‐Quinones, George Dennis Obeng, Benjamin Asiedu‐Ayeh, Sampson Kawuo, Asmau Mohammed Tukur, Inusah Mohammed, Akosua Pokuaah Obeng, Jean‐Luc Harousseau, Anja Seckinger, Dirk Hose, Emmanuel Sarkodie, Attila Imre, Marcell Csanádi   +12 more
wiley   +1 more source

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline

The Lancet Regional Health - Southeast Asia, 2023
Kinanti Khansa Chavarina, Dian Faradiba, Yot Teerawattananon   +2 more
openaire   +3 more sources

Cost‐Effectiveness of Venetoclax‐Based Treatment in Treatment‐Naïve Fit Patients With CLL Without TP53 Aberrations

European Journal of Haematology, EarlyView.
ABSTRACT The GAIA‐CLL13 trial showed that venetoclax‐obinutuzumab (Ven‐O) based regimens, with or without ibrutinib, offer superior efficacy compared to chemoimmunotherapy (CIT) with regards to progression free survival (PFS) in fit, treatment‐naïve (TN) CLL patients. However, their higher costs warrant a cost‐effectiveness evaluation.
Lars Holger Ehlers, Mark‐David Levin, Marjolein van der Klift, Morten Berg Jensen, Hoa Thi Tuyet Tran, Arnon Kater, Carsten Utoft Niemann   +6 more
wiley   +1 more source